Laing R W, Scalera I, Isaac J, Mergental H, Mirza D F, Hodson J, Wilkin R J W, Perera M T P R, Muiesan P
Department of Liver Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
NIHR Liver Biomedical Research Unit, University Hospitals Birmingham, Birmingham, UK.
Am J Transplant. 2016 Jun;16(6):1795-804. doi: 10.1111/ajt.13699. Epub 2016 Mar 3.
The use of livers from donation after circulatory death (DCD) is increasing, but concerns exist regarding outcomes following use of grafts from "marginal" donors. To compare outcomes in transplants using DCD and donation after brain death (DBD), propensity score matching was performed for 973 patients with chronic liver disease and/or malignancy who underwent primary whole-liver transplant between 2004 and 2014 at University Hospitals Birmingham NHS Foundation Trust. Primary end points were overall graft and patient survival. Secondary end points included postoperative, biliary and vascular complications. Over 10 years, 234 transplants were carried out using DCD grafts. Of the 187 matched DCDs, 82.9% were classified as marginal per British Transplantation Society guidelines. Kaplan-Meier analysis of graft and patient survival found no significant differences for either outcome between the paired DCD and DBD patients (p = 0.162 and p = 0.519, respectively). Aspartate aminotransferase was significantly higher in DCD recipients until 48 h after transplant (p < 0.001). The incidences of acute kidney injury and ischemic cholangiopathy were greater in DCD recipients (32.6% vs. 15% [p < 0.001] and 9.1% vs. 1.1% [p < 0.001], respectively). With appropriate recipient selection, the use of DCDs, including those deemed marginal, can be safe and can produce outcomes comparable to those seen using DBD grafts in similar recipients.
循环死亡后捐赠肝脏(DCD)的使用正在增加,但对于使用“边缘”供体的移植物后的结果存在担忧。为了比较使用DCD和脑死亡后捐赠(DBD)进行肝移植的结果,对2004年至2014年在伯明翰大学医院国民保健服务基金会信托中心接受初次全肝移植的973例慢性肝病和/或恶性肿瘤患者进行了倾向评分匹配。主要终点是移植物总体存活率和患者存活率。次要终点包括术后、胆道和血管并发症。在10多年的时间里,使用DCD移植物进行了234例肝移植。在187例匹配的DCD中,根据英国移植学会指南,82.9%被归类为边缘供体。对移植物和患者存活率进行的Kaplan-Meier分析发现,配对的DCD和DBD患者在这两种结果上均无显著差异(分别为p = 0.162和p = 0.519)。直到移植后48小时,DCD受者的天冬氨酸转氨酶水平显著更高(p < 0.001)。DCD受者急性肾损伤和缺血性胆管病的发生率更高(分别为32.6%对15% [p < 0.001]和9.1%对1.1% [p < 0.001])。通过适当选择受者,使用DCD,包括那些被视为边缘供体的DCD,可以是安全的,并且可以产生与在类似受者中使用DBD移植物所见结果相当的结果。